TransMedics Group, Inc. Common Stock
TMDX
$88.41
+5.39%
TransMedics Group, Inc. is a commercial-stage medical technology company that has developed the Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring platform designed to replace traditional cold storage methods for donor organs. The company operates in the medical devices industry, specifically focusing on organ transplant therapy for end-stage organ failure patients. As a pioneer in near-physiologic organ preservation, TransMedics holds a distinct competitive position as the only FDA-approved platform offering warm perfusion technology for lung, heart, and liver transplantation. The current investor narrative centers on the company's rapid revenue growth and expansion into international markets, particularly Europe, alongside recent earnings volatility and a significant stock price decline from its 52-week high, which has sparked debate about whether the pullback represents a buying opportunity or signals fundamental challenges.…
TMDX
TransMedics Group, Inc. Common Stock
$88.41
Related headlines
Investment Opinion: Should I buy TMDX Today?
We rate TMDX a Buy based on strong revenue growth (32% YoY), high gross margins (59.9%), and a reasonable trailing PE of 21.72x. The analyst consensus is Buy with an average target of $106, implying 32% upside. The company is profitable with positive free cash flow ($133.6M TTM), and its innovative OCS platform has a unique competitive position. However, the forward PE of 33.79x suggests near-term earnings pressure, and the stock's high beta (1.88) adds volatility. This Buy is contingent on the company maintaining growth above 20% and improving operating margins. If growth falls below 15% or margins deteriorate, we would downgrade to Hold. Overall, the stock appears undervalued relative to its growth potential, but investors should be prepared for significant price swings.
Sign up to view all
TMDX 12-Month Price Forecast
The AI model assesses TMDX as bullish over the next 12 months, driven by strong revenue growth and profitability. The stock's current valuation (trailing PE 21.72x) is attractive relative to growth, and analyst targets suggest upside. However, the high beta and recent volatility warrant caution. The stance would be upgraded to high confidence if the company delivers a strong Q2 2026 earnings report with revenue growth above 30% and improved margins. Conversely, a downgrade to neutral would occur if growth decelerates below 20% or if the stock breaks below the 52-week low of $60.105.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on TransMedics Group, Inc. Common Stock's 12-month outlook, with a consensus price target around $97.30 and implied upside of +10.1% versus the current price.
Average Target
$97.30
0 analysts
Implied Upside
+10.1%
vs. current price
Analyst Count
—
covering this stock
Price Range
$65 - $125
Analyst target range
TransMedics is covered by 10 analysts, with a consensus recommendation of 'Buy' and a mean recommendation score of 1.91 (where 1 is Strong Buy and 5 is Sell). The average target price is $106.00, implying an upside of approximately 32.2% from the current price of $80.21. The target price range spans from a low of $80.00 to a high of $125.00, with the low target essentially at the current price, suggesting some analysts see limited downside, while the high target implies a 55.8% upside. The wide spread between low and high targets (56.3% difference) indicates significant uncertainty about the company's future performance, likely due to the recent earnings miss and ongoing expansion risks.
Drowning in data?
Find the real signal!
Bulls vs Bears: TMDX Investment Factors
TransMedics presents a classic high-growth, high-risk investment. The bull case is anchored by strong revenue growth (32% YoY), high gross margins (59.9%), and profitability, with analysts seeing 32% upside. However, the bear case is equally compelling: the stock has been cut in half from its highs, forward PE suggests earnings decline, and high beta (1.88) amplifies volatility. The most critical tension is whether the recent earnings miss and stock decline reflect temporary growing pains or fundamental deterioration. If the company can sustain growth while expanding margins, the stock is undervalued; if not, further downside is possible. Currently, the bearish evidence (price action, forward PE) slightly outweighs the bullish fundamentals, but the analyst consensus and growth trajectory tilt the balance toward a cautious buy.
Bullish
- Strong Revenue Growth: Q4 2025 revenue grew 32.18% YoY to $160.764M, with sequential acceleration from $143.537M in Q1 to $160.764M in Q4. This demonstrates robust demand for the Organ Care System across lung, heart, and liver transplantation.
- High Gross Margin: Gross margin stood at 59.92% (trailing), with Q4 2025 at 58.11%. This indicates strong pricing power and a scalable business model, typical of innovative medical devices.
- Positive Net Income: The company reported net income of $105.383M in Q4 2025, with a net margin of 65.55% (boosted by a tax benefit). Trailing PE of 21.72x is reasonable for a growth company, and the company is profitable on a GAAP basis.
- Analyst Consensus Buy: 10 analysts rate TMDX a Buy with a mean score of 1.91 (1=Strong Buy). The average target price of $106.00 implies 32.2% upside from the current price of $80.21, suggesting Wall Street sees value.
Bearish
- Significant Stock Decline: The stock has fallen 32.48% over the past year and is down 40.61% over the last six months. It trades at $80.21, near the lower end of its 52-week range ($60.105-$156.0), reflecting a major de-rating.
- Forward PE Higher Than Trailing: Forward PE of 33.79x is higher than trailing PE of 21.72x, implying expected earnings decline. This is unusual for a growth company and suggests analysts anticipate margin compression or increased competition.
- High Volatility and Beta: Beta of 1.88 indicates the stock is highly sensitive to market movements. The max drawdown of -58.76% highlights the risk of significant losses, as seen in the recent drop from $156 to $60.
- Earnings Miss and Uncertainty: Recent earnings miss triggered a sharp selloff (stock fell from ~$95 to $72.92 in early May 2026). The wide analyst target range ($80-$125) indicates high uncertainty about future performance.
TMDX Technical Analysis
TransMedics is currently in a pronounced downtrend, with the stock price at $80.21 as of August 6, 2026, reflecting a 1-year decline of -32.48%. The stock is trading at approximately 51.4% of its 52-week range (current price of $80.21 relative to the low of $60.105 and high of $156.0), indicating it is closer to the lower end of its annual range. This positioning suggests the market has repriced the stock significantly from its highs, potentially reflecting a de-rating or fundamental concerns, but also leaving room for a potential recovery if sentiment shifts.
Beta
1.88
1.88x market volatility
Max Drawdown
-58.8%
Largest decline past year
52-Week Range
$60-$156
Price range past year
Annual Return
-22.8%
Cumulative gain past year
| Period | TMDX Return | S&P 500 |
|---|---|---|
| 1m | +24.1% | +2.4% |
| 3m | +38.3% | +4.7% |
| 6m | -33.7% | +11.7% |
| 1y | -22.8% | +21.3% |
| ytd | -27.9% | +13.4% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
TMDX Fundamental Analysis
TransMedics has demonstrated robust revenue growth, with Q4 2025 revenue of $160.764 million, representing a 32.18% year-over-year increase from $121.624 million in Q4 2024. The multi-quarter trend shows accelerating growth, with sequential revenue increases from $143.537 million in Q1 2025 to $157.370 million in Q2 2025, $143.823 million in Q3 2025, and $160.764 million in Q4 2025, indicating a strong growth trajectory. The company's product revenue, which constitutes the entire revenue base, was $100.39 million in the most recent quarter, underscoring the core business's strength. This growth is driven by the adoption of the Organ Care System in lung and heart transplantation, with expansion into liver and international markets providing additional tailwinds.
Quarterly Revenue
$160764000.0B
2025-12
Revenue YoY Growth
+32.2%
YoY Comparison
Gross Margin
58.1%
Latest Quarter
Free Cash Flow
$133589000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is TMDX Overvalued?
Given that TransMedics has positive net income, the price-to-earnings (PE) ratio is the most appropriate primary valuation metric. The trailing PE is 21.72x, while the forward PE is 33.79x, indicating that the market expects earnings to decline in the coming year, which is unusual for a growth company and may reflect anticipated margin pressures or increased competition. The gap between trailing and forward PE suggests a pessimistic outlook on near-term profitability, possibly due to investments in expansion or pricing dynamics.
PE
21.7x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range 10x~160x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
27.7x
Enterprise Value Multiple
Investment Risk Disclosure
Financial risks are substantial. The company carries a debt-to-equity ratio of 0.99, indicating significant leverage that could strain cash flows if revenue growth decelerates or interest rates rise. While the current ratio of 7.14 provides liquidity, the forward PE of 33.79x versus trailing 21.72x implies expected earnings decline, which could pressure the stock if realized. Additionally, the company's net margin of 31.4% (trailing) is partly due to a one-time tax benefit in Q4 2025; without it, profitability would be lower, making the stock more expensive on a normalized basis.
FAQ
The key risks are: 1) Financial risk: high debt-to-equity of 0.99 and forward PE of 33.79x imply potential earnings decline. 2) Market risk: beta of 1.88 means the stock is highly sensitive to market swings, and the max drawdown of -58.76% shows the potential for large losses. 3) Competitive risk: the OCS platform faces competition from other organ preservation technologies, and any new entrant could erode market share. 4) Company-specific risk: the recent earnings miss and stock decline highlight execution risks, especially in international expansion. The most severe risk is a prolonged downturn in growth, which could push the stock to the 52-week low of $60.105, a -25% downside from current levels.
Over the next 12 months, the base case scenario (45% probability) sees the stock trading around $95-$106, in line with the analyst average target. The bull case (30% probability) could push it to $125 if growth accelerates and margins improve. The bear case (25% probability) could see it fall to $60.105 if the company stumbles. The most likely outcome is a gradual recovery to the $100 level, assuming the company maintains its growth trajectory. Investors should watch for Q2 2026 earnings as a key catalyst.
Based on trailing earnings, TMDX trades at a PE of 21.72x, which is reasonable for a company growing revenue at 32%. However, the forward PE of 33.79x suggests the market expects earnings to decline, which could indicate overvaluation if that scenario materializes. Compared to the medical devices industry average PE of ~25x, the stock is fairly valued on trailing earnings but expensive on forward earnings. The PEG ratio of 0.05 (based on estimated EPS growth) suggests it is undervalued relative to growth, but this metric is distorted by the low trailing EPS. Overall, the stock is fairly valued to slightly undervalued, with the market pricing in near-term challenges.
TMDX is a good buy for growth-oriented investors with a high risk tolerance. The stock offers 32% upside to the average analyst target of $106, and the company is growing revenue at 32% YoY with a gross margin of 59.9%. However, the stock is highly volatile (beta 1.88) and has fallen 32% over the past year, so it's not suitable for conservative investors. A good entry point would be near the current price of $80, with a stop-loss below the 52-week low of $60.105.
TMDX is better suited for long-term investment (3-5 years) due to its high growth potential and the long adoption cycle for medical devices. The stock is too volatile for short-term trading, with a beta of 1.88 and frequent double-digit swings. The company's growth story, driven by the OCS platform and international expansion, will take time to play out. Short-term traders might find opportunities around earnings, but the risk is high. A minimum holding period of 3 years is recommended to ride out volatility and capture the growth potential.
